SEARCH:   Advanced

Blood, 15 February 2005, Vol. 105, No. 4, pp. 1566-1573. Prepublished online as a Blood First Edition Paper on October 7, 2004; DOI 10.1182/blood-2004-04-1233. This Article Full Text (PDF) All Versions of this Article: 2004-04-1233v1 105/4/1566    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mayr, C. Articles by Wendtner, C.-M. Search for Related Content PubMed PubMed Citation Articles by Mayr, C. Articles by Wendtner, C.-M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 1, 2004 Accepted September 30, 2004 Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) which allows expansion of specific CD8+ autologous T lymphocytes Christine Mayr, Dagmar Bund, Martin Schlee, Andreas Moosmann, David M Kofler, Michael Hallek, and Clemens-Martin Wendtner* KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich, Germany KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany Clinical Molecular Biology and Tumor Genetics, GSF-National Research Center for Environment and Health, Munich, Germany Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich, Germany; Medical Clinic I, University of Cologne, Cologne, Germany * Corresponding author; email: Clemens.Wendtner{at}uni-koeln.de. Fibromodulin (FMOD) was shown to be highly overexpressed in CLL cells compared to normal B lymphocytes by gene expression profiling. Therefore FMOD might serve as potential tumor associated antigen (TAA) in CLL enabling expansion of FMOD-specific T cells. In CLL samples derived from 16 different patients, high expression of FMOD by real-time RT-PCR was detectable in contrast to normal B lymphocytes. We used unpulsed native CLL cells and CD40 ligand (CD40L) stimulated CLL cells as antigen presenting cells (APC) to expand autologous T cells from 13 patients. The number of T cells during four weeks of in vitro culture increased 2 to 3.5-fold and the amount of T cells recognizing FMOD peptides bound to HLA-A2-dimers increased 10-fold. The expanded T cells were also able to secrete IFN- upon recognition of the antigen demonstrated by IFN--ELISPOT assays. T cells not only recognized HLA-A2 binding FMOD peptides presented by TAP-deficient T2 cells, but also FMOD overexpressing autologous CLL cells in an HLA-A2 restricted manner. In summary, FMOD was shown for the first time to be naturally processed and presented as TAA in primary CLL cells enabling the expansion of autologous tumor-specific T cells. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Nishida, M. Hudecek, A. Kostic, M. Bleakley, E. H. Warren, D. Maloney, R. Storb, and S. R. Riddell Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia Clin. Cancer Res., July 15, 2009; 15(14): 4759 - 4768. [Abstract] [Full Text] [PDF] A. W. Hauswirth and U. Jager Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia Haematologica, January 1, 2008; 93(1): 14 - 19. [Full Text] [PDF] S. Kalamajski and A. Oldberg Fibromodulin Binds Collagen Type I via Glu-353 and Lys-355 in Leucine-rich Repeat 11 J. Biol. Chem., September 14, 2007; 282(37): 26740 - 26745. [Abstract] [Full Text] [PDF] R. Godal, U. Keilholz, L. Uharek, A. Letsch, A. M. Asemissen, A. Busse, I.-K. Na, E. Thiel, and C. Scheibenbogen Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2 Blood, April 15, 2006; 107(8): 3205 - 3211. [Abstract] [Full Text] [PDF] A. Anichini, R. Mortarini, L. Romagnoli, P. Baldassari, A. Cabras, C. Carlo-Stella, A. M. Gianni, and M. Di Nicola Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with {gamma}c cytokines Blood, January 15, 2006; 107(2): 602 - 609. [Abstract] [Full Text] [PDF] C. Mayr, D. M. Kofler, H. Buning, D. Bund, M. Hallek, and C.-M. Wendtner Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells Blood, November 1, 2005; 106(9): 3223 - 3226. [Abstract] [Full Text] [PDF] E. Mikaelsson, A. H. Danesh-Manesh, A. Luppert, M. Jeddi-Tehrani, M.-R. Rezvany, R. A. Sharifian, R. Safaie, A. Roohi, A. Osterborg, F. Shokri, et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma Blood, June 15, 2005; 105(12): 4828 - 4835. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020